• Profile

Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis

JAMA Nov 17, 2021

Aminian A, Al-Kurd A, Wilson R, et al. - Researchers aimed at determining if bariatric surgery could aid in lowering the incidence of major adverse liver outcomes and major adverse cardiovascular events (MACE) in patients with obesity and biopsy-proven fibrotic nonalcoholic steatohepatitis (NASH) without cirrhosis.

  • In the SPLENDOR (Surgical Procedures and Long-term Effectiveness in NASH Disease and Obesity Risk) study, researchers identified a total of 1,158 adult patients with obesity who fulfilled enrollment criteria for this study, including confirmed histological diagnosis of NASH and presence of liver fibrosis (histological stages 1-3).

  • Of these patients, 650 patients underwent bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) and 508 patients received nonsurgical care.

  • Outcomes revealed a significant correlation of undergoing bariatric surgery with a lower risk of major adverse liver outcomes (adjusted absolute 10-year risk difference of 12.4%) and major adverse cardiovascular events (adjusted absolute 10-year risk difference of 13.9%).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen